Foghorn Therapeutics
Filed with the SEC on · accession 0001628280-26-071871
FHTX filed a 8-K (current report) with the SEC on Nov 9, 2026. A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
Foghorn Therapeutics issued a press release announcing its financial results for the quarter ended September 30, 2026, and furnished an investor presentation for use in investor meetings.
✦ Ask GOAX AI about this filing — what it means for FHTX, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for FHTX?
Click hereFHTX filed a 8-K (SEC filing). Foghorn Therapeutics issued a press release announcing its financial results for the quarter ended September 30, 2026, and furnished an investor presentation for use in investor meetings.
A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
Get alerts when FHTX files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days